Person experiencing digestive wellness in a Japanese garden setting.

Is Your Gut in Distress? Comparing Treatments for Functional Dyspepsia

Beau Callahan in Health & Wellness December 2025 • 4 min read.

"A landmark study reveals how rabeprazole and itopride stack up in relieving digestive woes."

Do you often experience discomfort after eating, such as bloating, nausea, or a burning sensation in your upper abdomen? If so, you might be one of the many people who suffer from functional dyspepsia (FD). FD is a common condition characterized by these persistent digestive symptoms, even when tests reveal no underlying organic cause.

Functional dyspepsia is categorized into two main types: postprandial distress syndrome (PDS), which involves fullness and early satiety after meals, and epigastric pain syndrome (EPS), characterized by pain or burning in the stomach area. While various medications are used to manage FD, finding the most effective approach can be challenging.

A recent study conducted in Japan, known as the NAGOYA study, aimed to compare the effectiveness of two commonly used medications for FD: rabeprazole (RPZ), a proton pump inhibitor (PPI) that reduces stomach acid production, and itopride (ITO), a prokinetic agent that helps to speed up gastric emptying. Let's dive into the findings of this research and explore how these treatments can help alleviate the burden of functional dyspepsia.

Rabeprazole vs. Itopride: Which Treatment Reigns Supreme for Functional Dyspepsia?

Person experiencing digestive wellness in a Japanese garden setting.

The NAGOYA study, a multicenter randomized trial, involved 134 patients diagnosed with FD according to the Rome III criteria. These patients were randomly assigned to receive either rabeprazole (10 mg/day) or itopride (150 mg/day) for four weeks. Throughout the study, researchers evaluated the severity of dyspeptic symptoms using FD scores, which assessed both EPS and PDS symptoms.

So, what did the study reveal? Here's a breakdown of the key findings:

Rapid Relief with Rabeprazole: Rabeprazole demonstrated a significant decrease in FD scores within the first week of treatment, and this improvement was sustained throughout the four-week study period.
Superior Efficacy of Rabeprazole: Rabeprazole outperformed itopride at all evaluation points, indicating a more pronounced effect in reducing overall FD symptoms.
Broad-Spectrum Relief with Rabeprazole: Rabeprazole significantly reduced FD scores in patients with both EPS and PDS, suggesting its effectiveness in addressing a wide range of dyspeptic symptoms.
Targeted Relief with Itopride: Itopride showed a significant decrease in FD scores only in patients with predominant PDS, suggesting its potential benefit in managing symptoms related to delayed gastric emptying.

These results suggest that rabeprazole, an acid-suppressive therapy, may be a valuable option for managing both PDS and EPS in Japanese patients with FD. On the other hand, itopride, a prokinetic agent, may be more specifically suited for individuals with PDS-predominant FD.

Navigating Your Path to Digestive Wellness

The NAGOYA study provides valuable insights into the management of functional dyspepsia, highlighting the potential benefits of both rabeprazole and itopride. If you're struggling with persistent digestive symptoms, it's essential to consult with your healthcare provider to determine the most appropriate treatment approach for your individual needs. Together, you can explore the options and find a strategy that helps you regain control over your digestive health and improve your overall well-being.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is functional dyspepsia (FD), and how is it categorized?

Functional dyspepsia (FD) is a condition characterized by persistent digestive symptoms such as bloating, nausea, or burning sensations, even when tests don't reveal an underlying organic cause. It's primarily categorized into two types: postprandial distress syndrome (PDS), involving fullness and early satiety after meals, and epigastric pain syndrome (EPS), characterized by pain or burning in the stomach area. Determining which type of FD a patient has is crucial for selecting the most appropriate treatment, as different medications may target PDS and EPS more effectively.

How does rabeprazole work to alleviate functional dyspepsia symptoms, and what were the key findings regarding its effectiveness?

Rabeprazole (RPZ) is a proton pump inhibitor (PPI) that reduces stomach acid production. The NAGOYA study revealed that Rabeprazole significantly decreased FD scores within the first week of treatment, an improvement that was sustained throughout the four-week study. Rabeprazole outperformed itopride at all evaluation points, indicating a more pronounced effect in reducing overall FD symptoms. It also significantly reduced FD scores in patients with both EPS and PDS, suggesting its effectiveness in addressing a wide range of dyspeptic symptoms.

What is itopride, and on which specific symptoms of functional dyspepsia did it demonstrate a significant effect in the NAGOYA study?

Itopride (ITO) is a prokinetic agent that helps to speed up gastric emptying. In the NAGOYA study, itopride showed a significant decrease in FD scores only in patients with predominant postprandial distress syndrome (PDS). This suggests itopride may be particularly beneficial for managing symptoms related to delayed gastric emptying, a common issue in individuals with PDS. It did not show a significant effect on epigastric pain syndrome (EPS).

According to the NAGOYA study, what are the implications of using rabeprazole versus itopride for treating functional dyspepsia?

The NAGOYA study suggests that rabeprazole, an acid-suppressive therapy, may be a valuable option for managing both postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) in Japanese patients with functional dyspepsia. On the other hand, itopride, a prokinetic agent, may be more specifically suited for individuals with PDS-predominant FD. These findings highlight the importance of tailoring treatment to the specific type of FD and the predominant symptoms experienced by the patient.

What considerations should individuals with persistent digestive symptoms keep in mind when exploring treatment options for functional dyspepsia?

Individuals struggling with persistent digestive symptoms should consult with their healthcare provider to determine the most appropriate treatment approach for their individual needs. The NAGOYA study provides valuable insights into the potential benefits of both rabeprazole and itopride, but the choice of medication should be based on a comprehensive evaluation of the patient's symptoms, medical history, and any other relevant factors. A healthcare provider can help explore the available options and develop a strategy to regain control over digestive health and improve overall well-being. Understanding whether symptoms align more with postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS) is an important first step.